FDA WARNING_LETTER - Rebuilder Medical, Inc. - January 11, 2011
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On March 8, 2011, the FDA issued a Warning Letter to ReBuilder Medical, Inc. following a January 4 and 11, 2011 inspection. The inspection revealed that the firm's ReBuilder™ Transcutaneous Nerve Stimulator and ReBuilder™ Bucket Transcutaneous Nerve Stimulator devices are adulterated under section 501(h) of the Act, as their manufacturing, packing, storage, or installation methods, facilities, or controls do not conform to the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) regulation (21 C.F.R. Part 820).
The FDA found multiple violations, including: 1. **Failure to maintain non-conforming product procedures (21 C.F.R. 820.90(a)):** Complaint logs lacked documentation of receipt dates, investigations, conclusions, and disposition dates for returned devices. The firm's response was inadequate, failing to explain compliance assurance or employee training plans for revised procedures. 2. **Failure to establish rework procedures (21 CFR 820.90(b)(2)):** No procedures or adequate records for rework of non-conforming signal generator components were maintained. 11.6% of signal generator components required rework between 10/25/2010 and 11/30/2010.
ID · 70be398a-5a1a-407e-bec8-71bc8daeede5
Full citation text and observation details available on the Dashboard.